Invitrogen™ Tobemstomig Recombinant Human Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Tobemstomig is a biosimilar that acts as a bispecific monoclonal antibody targeting the PD-1 (programmed cell death protein 1) and LAG-3 (lymphocyte-activation gene 3) checkpoints. Lymphocyte Activation Gene-3 (LAG3) is a type I transmembrane protein with structural similarities to CD4 and is encoded by the LAG3 gene located on chromosome 12p13. The protein is highly upregulated on exhausted T cells in the tumor microenvironment and functions as an immune checkpoint receptor. Upon binding to MHC class II molecules, LAG3 transmits inhibitory signals to T cells, leading to T cell dysfunction, making it a significant target for cancer immunotherapy. PDCD1, on the other hand, encodes the Programmed Cell Death Protein 1 (PD-1), which is found on chromosome 2q37.3. PD-1 is a receptor expressed on the surface of immune cells, particularly T cells, and interacts with its ligands PD-L1 and PD-L2 to suppress T cell inflammatory activity, thus preventing autoimmunity. Both LAG3 and PD-1 play crucial roles in modulating immune responses, particularly through their inhibitory actions in the tumor microenvironment. These genes are primarily targeted in combination cancer immunotherapies aimed at restoring the immune system's ability to eradicate cancer cells.